Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for

Status Recruiting

Clinical Trial Summary

This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.

Clinical Trial Description

Stroke has been one of the most important causes of disability and death worldwide today. Ischemic stroke accounts for more than 50% of these strokes. The results of epidemiological surveys show that in 2018, more than 3 million new strokes occurred each year in China. In 2018, more than 3 million people suffered from a stroke, and more than 2 million people died from a stroke. Studies show that about 25% to 40% of transient ischemic attacks (TIA) or strokes occur in the posterior circulation. The subclavian and vertebral arteries are important blood vessels in the posterior circulation and are important original sites for ischemic strokes in the posterior circulation. About 20% of strokes in the posterior circulation are caused by extracranial vertebral artery stenosis (ECVAS). Endovascular intervention is the recommended treatment for ECVAS. It is effective in promoting the perfusion of brain tissue in the area of the responsible artery, thereby reducing the risk of stroke recurrence, improving neurological prognosis, and reducing symptoms. The drug-eluting stent is effective in reducing the incidence of postoperative restenosis (ISR), thus further reducing the long-term risk of stroke. Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials. The purpose of this study is to further investigate its long-term effectiveness in treating vertebral artery stenosis in the real world. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05644314
Study type	Interventional
Source	Nanfang Hospital of Southern Medical University
Contact	Zhong Ji, PHD
Phone	020-62787664
Email	jizhong22@hotmail.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2022
Completion date	May 31, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05196659` - Collaborative Quality Improvement (C-QIP) Study	N/A
Recruiting	`NCT06027788` - CTSN Embolic Protection Trial	N/A
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT05518305` - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting	`NCT06029959` - Stroke and CPAP Outcome Study 3	N/A
Recruiting	`NCT03728738` - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke	Phase 3
Terminated	`NCT03396419` - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting	`NCT05065216` - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)	Phase 2/Phase 3
Recruiting	`NCT04897334` - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke	N/A
Not yet recruiting	`NCT06462599` - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting	`NCT06032819` - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting	`NCT06026696` - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting	`NCT02910180` - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn	`NCT01866189` - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke	N/A
Completed	`NCT02922452` - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT03554642` - Walkbot Robotic Training for Improvement in Gait	Phase 3
Recruiting	`NCT03041753` - Reperfusion Injury After Stroke Study	N/A
Completed	`NCT02549846` - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial	Phase 4
Completed	`NCT01678534` - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial	Phase 2
Completed	`NCT02610803` - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms